

**Table S1** Body weight changes during AML treatment cycles.

<b>Parameter</b>	<b>all patients</b>	<b>with TPN</b>	<b>without TPN</b>	<b>p</b>
<b>Patients, n</b>	126	75	51	
Delta weight cycle 1, kg (range), n	-3.2 (-20.9-5)	-3.5 (-12.9-4)	-2.1 (-20.9-5)	0.956
Delta BMI cycle 1, kg/m <sup>2</sup> (range), n	-1.1 (-6.2-1.7)	-1.2 (-4-1.6)	-0.9 (-6.2-1.7)	0.823
Delta weight between cycles 1&2, kg (range), n	0 (-8-10.7)	-0.2 (-8-7.7)	0.7 (-8-10.7)	0.212
Delta BMI between cycles 1& 2, kg/m <sup>2</sup> (range), n	-0.1 (-2.8-3.4)	-0.1 (-2.4-3.4)	0 (-2.8-3.3)	0.485
Delta weight cycle 2, kg (range), n	-1.1 (-7-3.8)	-1 (-7-3.8)	-1.9 (-7-3.8)	0.338
Delta BMI cycle 2, kg/m <sup>2</sup> (range), n	0.4 (-1.6-2.5)	0.4 (-1.6-2.5)	0.4 (-1.6-2.5)	0.905
Delta weight between FD & Apheresis, kg (range), n	-4.5 (-20.5-3.4)	-4.5 (-16.1-3)	-4.4 (-20.5-3.4)	0.450
Delta BMI between FD & Apheresis, kg/m <sup>2</sup> (range), n	-1.6 (-7.3-1.2)	-1.7 (-5.6-1)	-1.5 (-7.3-1.2)	0.389
Delta weight between cycle 2 & HDC, kg (range), n	2 (-4.8-13.5)	1.3 (-4.8-13.5)	3 (-3.5-11)	0.439
Delta BMI between cycle 2 & HDC, kg/m <sup>2</sup> (range), n	0.8 (-1.8-4.8)	0.6 (-1.8-4.8)	1.1 (0.2-3.2)	0.196
Delta weight HDC, kg (range), n	-2.3 (-8.6-1.2)	-2.2 (-8.4-1.1)	-2.5 (-8.6-1.2)	0.415
Delta BMI HDC, kg/m <sup>2</sup> (range), n	-0.7 (-2.9-1.1)	-0.7 (-2.9-1.1)	-0.9 (-2.9-0.5)	0.725

BMI, Body mass index; FD, First diagnosis; HDC, High dose cycle

**Table S2** Characteristics of the disease in patients of this study.

Parameter	all patients	with TPN	without TPN	p
<b>Patients, n</b>	126	75	51	
<b>AML-FAB</b>				
M0, n (%)	12 (10)	6 (8)	6 (12)	0.647
M1, n (%)	29 (23)	15 (20)	14 (27)	0.647
M2, n (%)	39 (31)	21 (28)	18 (35)	0.647
M4, n (%)	21 (17)	16 (21)	5 (10)	0.647
M5, n (%)	10 (8)	6 (8)	4 (8)	0.647
M6, n (%)	1 (1)	1 (1)	0 (0)	0.647
Secondary AML (therapy related), n (%)	5 (4)	2 (3)	3 (6)	0.647
Secondary AML (MDS related), n (%)	10 (8)	6 (8)	4 (8)	0.647
Others, n (%)	13 (10)	6 (8)	7 (14)	0.647
<b>Genetic diagnostics</b>				
Normal karyotypes, n (%)	78 (62)	47 (63)	31 (61)	0.815
complex abnormalities, n (%)	7 (6)	3 (4)	4 (8)	0.815
del(7q)	3 (2)	3 (4)	0 (0)	0.815
del(5q), n (%)	2 (2)	2 (3)	0 (0)	0.815
del(9q), n (%)	3 (2)	2 (3)	1 (2)	0.815
others, n (%)	14 (11)	6 (8)	8 (16)	0.815
<i>NPM1</i> mut with <i>FLT3</i> wt, n (%)	27 (21)	19 (25)	8 (16)	0.335
<i>NPM1</i> mut with <i>FLT3</i> - ITD, n (%)	14 (11)	10 (13)	4 (8)	0.335
<i>FLT3</i> -ITD with <i>NPM1</i> wt, n (%)	11 (9)	8 (11)	3 (6)	0.335
<i>c-KIT</i> , n (%)	2 (2)	2 (3)	0 (0)	0.335
<i>CEBPA</i> -mutation, n (%)	5 (4)	3 (4)	2 (4)	0.335
Biallelic <i>CEBPA</i> -mutation, n (%)	1 (1)	0 (0)	1 (2)	0.335
<i>RUNX1-RUNX1T1</i> /t(8;21), n (%)	15 (12)	9 (12)	6 (12)	0.335
<i>BCR-ABL1</i> /t(9;22), n (%)	3 (2)	2 (3)	1 (2)	0.335
<i>CBFb-MYH11</i> /inv(16), n (%)	9 (7)	7 (9)	2 (4)	0.335
others, n (%)	6 (5)	2 (3)	4 (8)	0.335
not available, n (%)	3 (2)	1 (1)	2 (4)	0.335